{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T21:17:39Z","timestamp":1794431859666,"version":"4.9.1"},"reference-count":76,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T00:00:00Z","timestamp":1765756800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T00:00:00Z","timestamp":1765756800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000925","name":"Department of Health | National Health and Medical Research Council","doi-asserted-by":"publisher","award":["APP2003150"],"award-info":[{"award-number":["APP2003150"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"Department of Health | National Health and Medical Research Council","doi-asserted-by":"publisher","award":["APP1153961"],"award-info":[{"award-number":["APP1153961"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Chemotherapy often kills a large fraction of cancer cells but leaves behind a small population of drug-tolerant persister cells. These persister cells survive drug treatments through reversible, non-genetic mechanisms and cause tumour recurrence upon cessation of therapy. Here, we report a drug tolerance mechanism regulated by the germ-cell-specific H3K4 methyltransferase PRDM9. Through histone proteomic, transcriptomic, lipidomic, and ChIP-sequencing studies combined with CRISPR knockout and phenotypic drug screen, we identify that chemotherapy-induced PRDM9 upregulation promotes metabolic rewiring in glioblastoma stem cells, leading to chemotherapy tolerance. Mechanistically, PRDM9-dependent H3K4me3 at cholesterol biosynthesis genes enhances cholesterol biosynthesis, which persister cells rely on to maintain homeostasis under chemotherapy-induced oxidative stress and lipid peroxidation. PRDM9 inhibition, combined with chemotherapy, results in strong anti-cancer efficacy in preclinical glioblastoma models, significantly enhancing the magnitude and duration of the antitumor response by eliminating persisters. These findings demonstrate a role of PRDM9 in promoting metabolic reprogramming that enables the survival of drug-tolerant persister cells.<\/jats:p>","DOI":"10.1038\/s41467-025-65888-5","type":"journal-article","created":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T10:02:15Z","timestamp":1765792935000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Histone methyltransferase PRDM9 promotes survival of drug-tolerant persister cells in glioblastoma"],"prefix":"10.1038","volume":"16","author":[{"given":"George L.","family":"Joun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-8470-6402","authenticated-orcid":false,"given":"Emma G.","family":"Kempe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brianna","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jayden R.","family":"Sterling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8007-4648","authenticated-orcid":false,"given":"Ramzi H.","family":"Abbassi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2526-4451","authenticated-orcid":false,"given":"Dana","family":"Friess","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Singleton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chandra","family":"Choudhury","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5629-7884","authenticated-orcid":false,"given":"Oana C.","family":"Marian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W. Daniel","family":"du Preez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ariadna","family":"Recasens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teleri","family":"Clark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0674-361X","authenticated-orcid":false,"given":"Tian Y.","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0862-0012","authenticated-orcid":false,"given":"Jason K. K.","family":"Low","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hani","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1098-3138","authenticated-orcid":false,"given":"Pengyi","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jasmine","family":"Khor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monira","family":"Hoque","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8837-5883","authenticated-orcid":false,"given":"Dinesh C.","family":"Indurthi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mani","family":"Kuchibhotla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ranjith","family":"Palanisamy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William T.","family":"Jorgensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew P.","family":"Montgomery","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer R.","family":"Baker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah L.","family":"Higginbottom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Tomaskovic-Crook","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6415-1639","authenticated-orcid":false,"given":"Jeremy M.","family":"Crook","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4112-1816","authenticated-orcid":false,"given":"Lipin","family":"Loo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bryan W.","family":"Day","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1957-9732","authenticated-orcid":false,"given":"G. Gregory","family":"Neely","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7764-5307","authenticated-orcid":false,"given":"Ernesto","family":"Guccione","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terrance G.","family":"Johns","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6655-0529","authenticated-orcid":false,"given":"Michael","family":"Kassiou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuchen","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lachlan","family":"Harris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1655-1184","authenticated-orcid":false,"given":"Anthony S.","family":"Don","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7625-5646","authenticated-orcid":false,"given":"Lenka","family":"Munoz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,15]]},"reference":[{"key":"65888_CR1","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1038\/s41571-023-00815-5","volume":"20","author":"Y Pu","year":"2023","unstructured":"Pu, Y. et al. Drug-tolerant persister cells in cancer: the cutting edges and future directions. Nat. Rev. Clin. Oncol. 20, 799\u2013813 (2023).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"65888_CR2","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.cell.2010.02.027","volume":"141","author":"SV Sharma","year":"2010","unstructured":"Sharma, S. V. et al. A Chromatin-Mediated Reversible Drug-Tolerant State in Cancer Cell Subpopulations. Cell 141, 69\u201380 (2010).","journal-title":"Cell"},{"key":"65888_CR3","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms10690","volume":"7","author":"M Ramirez","year":"2016","unstructured":"Ramirez, M. et al. Diverse drug-resistance mechanisms can emerge from drug-tolerant cancer persister cells. Nat. Commun. 7, 10690 (2016).","journal-title":"Nat. Commun."},{"key":"65888_CR4","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1038\/s41568-024-00737-z","volume":"24","author":"M Russo","year":"2024","unstructured":"Russo, M. et al. Cancer drug-tolerant persister cells: from biological questions to clinical opportunities. Nat. Rev. Cancer 24, 694\u2013717 (2024).","journal-title":"Nat. Rev. Cancer"},{"key":"65888_CR5","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1056\/NEJMoa043330","volume":"352","author":"R Stupp","year":"2005","unstructured":"Stupp, R. et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med. 352, 987\u2013996 (2005).","journal-title":"N. Engl. J. Med."},{"key":"65888_CR6","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-024-05234-3","volume":"22","author":"JJ Vicente","year":"2024","unstructured":"Vicente, J. J. et al. The microtubule targeting agent ST-401 triggers cell death in interphase and prevents the formation of polyploid giant cancer cells. J. Transl. Med. 22, 441 (2024).","journal-title":"J. Transl. Med."},{"key":"65888_CR7","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1158\/1535-7163.MCT-23-0179","volume":"22","author":"A Ehteda","year":"2023","unstructured":"Ehteda, A. et al. Microtubule-Targeting Combined with HDAC Inhibition Is a Novel Therapeutic Strategy for Diffuse Intrinsic Pontine Gliomas. Mol. Cancer Therapeutics 22, 1413\u20131421 (2023).","journal-title":"Mol. Cancer Therapeutics"},{"key":"65888_CR8","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1021\/acsptsci.9b00045","volume":"2","author":"RH Abbassi","year":"2019","unstructured":"Abbassi, R. H. et al. Lower Tubulin Expression in Glioblastoma Stem Cells Attenuates Efficacy of Microtubule-Targeting Agents. ACS Pharmacol. Transl. Sci. 2, 402\u2013413 (2019).","journal-title":"ACS Pharmacol. Transl. Sci."},{"key":"65888_CR9","doi-asserted-by":"publisher","first-page":"5650","DOI":"10.3390\/cancers13225650","volume":"13","author":"L Wordeman","year":"2021","unstructured":"Wordeman, L. & Vicente, J. J. Microtubule Targeting Agents in Disease: Classic Drugs, Novel Roles. Cancers (Basel) 13, 5650 (2021).","journal-title":"Cancers (Basel)"},{"key":"65888_CR10","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1038\/nature16071","volume":"528","author":"M Osswald","year":"2015","unstructured":"Osswald, M. et al. Brain tumour cells interconnect to a functional and resistant network. Nature 528, 93\u201398 (2015).","journal-title":"Nature"},{"key":"65888_CR11","doi-asserted-by":"publisher","first-page":"2899","DOI":"10.1016\/j.cell.2022.06.054","volume":"185","author":"V Venkataramani","year":"2022","unstructured":"Venkataramani, V. et al. Glioblastoma hijacks neuronal mechanisms for brain invasion. Cell 185, 2899\u20132917.e2831 (2022).","journal-title":"Cell"},{"key":"65888_CR12","doi-asserted-by":"publisher","first-page":"5943","DOI":"10.1021\/acs.jmedchem.6b01469","volume":"60","author":"Z Rankovic","year":"2017","unstructured":"Rankovic, Z. CNS Physicochemical Property Space Shaped by a Diverse Set of Molecules with Experimentally Determined Exposure in the Mouse Brain. J. Medicinal Chem. 60, 5943\u20135954 (2017).","journal-title":"J. Medicinal Chem."},{"key":"65888_CR13","doi-asserted-by":"publisher","DOI":"10.1093\/noajnl\/vdaa165","volume":"3","author":"EA Horne","year":"2021","unstructured":"Horne, E. A. et al. A brain-penetrant microtubule-targeting agent that disrupts hallmarks of glioma tumorigenesis. Neuro-Oncol. Adv. 3, vdaa165 (2021).","journal-title":"Neuro-Oncol. Adv."},{"key":"65888_CR14","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1007\/s10637-023-01336-9","volume":"41","author":"M Joerger","year":"2023","unstructured":"Joerger, M. et al. Safety and anti-tumor activity of lisavanbulin administered as 48-hour infusion in patients with ovarian cancer or recurrent glioblastoma: a phase 2a study. Investig. N. Drugs 41, 267\u2013275 (2023).","journal-title":"Investig. N. Drugs"},{"key":"65888_CR15","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-40579-1","volume":"14","author":"Q Cai","year":"2023","unstructured":"Cai, Q. et al. Optical blood-brain-tumor barrier modulation expands therapeutic options for glioblastoma treatment. Nat. Commun. 14, 4934 (2023).","journal-title":"Nat. Commun."},{"key":"65888_CR16","doi-asserted-by":"publisher","first-page":"1669","DOI":"10.1016\/j.celrep.2017.04.077","volume":"19","author":"MP Dalvi","year":"2017","unstructured":"Dalvi, M. P. et al. Taxane-Platin-Resistant Lung Cancers Co-develop Hypersensitivity to JumonjiC Demethylase Inhibitors. Cell Rep. 19, 1669\u20131684 (2017).","journal-title":"Cell Rep."},{"key":"65888_CR17","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.1111\/febs.15844","volume":"289","author":"F Di Tullio","year":"2022","unstructured":"Di Tullio, F., Schwarz, M., Zorgati, H., Mzoughi, S. & Guccione, E. The duality of PRDM proteins: epigenetic and structural perspectives. Febs j. 289, 1256\u20131275 (2022).","journal-title":"Febs j."},{"key":"65888_CR18","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/bs.ctdb.2022.06.002","volume":"151","author":"IF Sou","year":"2023","unstructured":"Sou, I. F., Hamer, G., Tee, W. W., Vader, G. & McClurg, U. L. Cancer and meiotic gene expression: Two sides of the same coin?. Curr. Top. Dev. Biol. 151, 43\u201368 (2023).","journal-title":"Curr. Top. Dev. Biol."},{"key":"65888_CR19","doi-asserted-by":"publisher","first-page":"16522","DOI":"10.3390\/ijms242216522","volume":"24","author":"P Ladias","year":"2023","unstructured":"Ladias, P. et al. Cancer Associated PRDM9: Implications for Linking Genomic Instability and Meiotic Recombination. Int J. Mol. Sci. 24, 16522 (2023).","journal-title":"Int J. Mol. Sci."},{"key":"65888_CR20","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.1101\/gr.231696.117","volume":"28","author":"AA Houle","year":"2018","unstructured":"Houle, A. A. et al. Aberrant PRDM9 expression impacts the pan-cancer genomic landscape. Genome Res 28, 1611\u20131620 (2018).","journal-title":"Genome Res"},{"key":"65888_CR21","doi-asserted-by":"publisher","DOI":"10.1038\/cddiscovery.2015.28","volume":"1","author":"F Gurgis","year":"2015","unstructured":"Gurgis, F. et al. Cytotoxic activity of the MK2 inhibitor CMPD1 in glioblastoma cells is independent of MK2. Cell Death Discov. 1, 15028 (2015).","journal-title":"Cell Death Discov."},{"key":"65888_CR22","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1038\/nmeth.3853","volume":"13","author":"M Hafner","year":"2016","unstructured":"Hafner, M., Niepel, M., Chung, M. & Sorger, P. K. Growth rate inhibition metrics correct for confounders in measuring sensitivity to cancer drugs. Nat. Methods 13, 521 (2016).","journal-title":"Nat. Methods"},{"key":"65888_CR23","doi-asserted-by":"publisher","first-page":"3087","DOI":"10.1158\/0008-5472.CAN-12-3256","volume":"73","author":"R Katayama","year":"2013","unstructured":"Katayama, R. et al. Cytotoxic Activity of Tivantinib (ARQ 197) Is Not Due Solely to c-MET Inhibition. Cancer Res. 73, 3087\u20133096 (2013).","journal-title":"Cancer Res."},{"key":"65888_CR24","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1016\/j.phrs.2018.06.023","volume":"134","author":"M Hoque","year":"2018","unstructured":"Hoque, M. et al. Changes in cell morphology guide identification of tubulin as the off-target for protein kinase inhibitors. Pharmacol. Res. 134, 166\u2013178 (2018).","journal-title":"Pharmacol. Res."},{"key":"65888_CR25","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-36829-x","volume":"14","author":"JL Dahlin","year":"2023","unstructured":"Dahlin, J. L. et al. Reference compounds for characterizing cellular injury in high-content cellular morphology assays. Nat. Commun. 14, 1364 (2023).","journal-title":"Nat. Commun."},{"key":"65888_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2020.108421","volume":"33","author":"S Shen","year":"2020","unstructured":"Shen, S. et al. Melanoma Persister Cells Are Tolerant to BRAF\/MEK Inhibitors via ACOX1-Mediated Fatty Acid Oxidation. Cell Rep. 33, 108421 (2020).","journal-title":"Cell Rep."},{"key":"65888_CR27","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1016\/j.ccell.2019.08.006","volume":"36","author":"AP Gomes","year":"2019","unstructured":"Gomes, A. P. et al. Dynamic Incorporation of Histone H3 Variants into Chromatin Is Essential for Acquisition of Aggressive Traits and Metastatic Colonization. Cancer Cell 36, 402\u2013417.e413 (2019).","journal-title":"Cancer Cell"},{"key":"65888_CR28","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms6210","volume":"5","author":"LF Duarte","year":"2014","unstructured":"Duarte, L. F. et al. Histone H3.3 and its proteolytically processed form drive a cellular senescence programme. Nat. Commun. 5, 5210 (2014).","journal-title":"Nat. Commun."},{"key":"65888_CR29","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/j.stem.2016.11.003","volume":"20","author":"BB Liau","year":"2017","unstructured":"Liau, B. B. et al. Adaptive Chromatin Remodeling Drives Glioblastoma Stem Cell Plasticity and Drug Tolerance. Cell Stem Cell 20, 233\u2013246.e237 (2017).","journal-title":"Cell Stem Cell"},{"key":"65888_CR30","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-13652-x","volume":"10","author":"A Allali-Hassani","year":"2019","unstructured":"Allali-Hassani, A. et al. Discovery of a chemical probe for PRDM9. Nat. Commun. 10, 5759 (2019).","journal-title":"Nat. Commun."},{"key":"65888_CR31","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-41277-z","volume":"9","author":"BW Stringer","year":"2019","unstructured":"Stringer, B. W. et al. A reference collection of patient-derived cell line and xenograft models of proneural, classical and mesenchymal glioblastoma. Sci. Rep. 9, 4902 (2019).","journal-title":"Sci. Rep."},{"key":"65888_CR32","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1038\/nchembio.2085","volume":"12","author":"M Vinogradova","year":"2016","unstructured":"Vinogradova, M. et al. An inhibitor of KDM5 demethylases reduces survival of drug-tolerant cancer cells. Nat. Chem. Biol. 12, 531\u2013538 (2016).","journal-title":"Nat. Chem. Biol."},{"key":"65888_CR33","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1038\/s41576-020-0278-0","volume":"22","author":"BK Cenik","year":"2021","unstructured":"Cenik, B. K. & Shilatifard, A. COMPASS and SWI\/SNF complexes in development and disease. Nat. Rev. Genet. 22, 38\u201358 (2021).","journal-title":"Nat. Rev. Genet."},{"key":"65888_CR34","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1038\/nature04112","volume":"438","author":"K Hayashi","year":"2005","unstructured":"Hayashi, K., Yoshida, K. & Matsui, Y. A histone H3 methyltransferase controls epigenetic events required for meiotic prophase. Nature 438, 374\u2013378 (2005).","journal-title":"Nature"},{"key":"65888_CR35","doi-asserted-by":"publisher","first-page":"10660","DOI":"10.1073\/pnas.0600447103","volume":"103","author":"LT Vassilev","year":"2006","unstructured":"Vassilev, L. T. et al. Selective small-molecule inhibitor reveals critical mitotic functions of human CDK1. Proc. Natl. Acad. Sci. USA 103, 10660\u201310665 (2006).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"65888_CR36","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1016\/j.cell.2014.06.027","volume":"158","author":"BA Benayoun","year":"2014","unstructured":"Benayoun, B. A. et al. H3K4me3 breadth is linked to cell identity and transcriptional consistency. Cell 158, 673\u2013688 (2014).","journal-title":"Cell"},{"key":"65888_CR37","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.28383","volume":"6","author":"N Altemose","year":"2017","unstructured":"Altemose, N. et al. A map of human PRDM9 binding provides evidence for novel behaviors of PRDM9 and other zinc-finger proteins in meiosis. Elife 6, e28383 (2017).","journal-title":"Elife"},{"key":"65888_CR38","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1091\/mbc.e16-09-0686","volume":"28","author":"ED Parvanov","year":"2017","unstructured":"Parvanov, E. D. et al. PRDM9 interactions with other proteins provide a link between recombination hotspots and the chromosomal axis in meiosis. Mol. Biol. Cell 28, 488\u2013499 (2017).","journal-title":"Mol. Biol. Cell"},{"key":"65888_CR39","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-20225-w","volume":"11","author":"Y Wu","year":"2020","unstructured":"Wu, Y. et al. Glioblastoma epigenome profiling identifies SOX10 as a master regulator of molecular tumour subtype. Nat. Commun. 11, 6434 (2020).","journal-title":"Nat. Commun."},{"key":"65888_CR40","doi-asserted-by":"publisher","first-page":"e1006146","DOI":"10.1371\/journal.pgen.1006146","volume":"12","author":"NR Powers","year":"2016","unstructured":"Powers, N. R. et al. The Meiotic Recombination Activator PRDM9 Trimethylates Both H3K36 and H3K4 at Recombination Hotspots In Vivo. PLoS Genet 12, e1006146 (2016).","journal-title":"PLoS Genet"},{"key":"65888_CR41","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1038\/nrc.2016.76","volume":"16","author":"PJ Mullen","year":"2016","unstructured":"Mullen, P. J., Yu, R., Longo, J., Archer, M. C. & Penn, L. Z. The interplay between cell signalling and the mevalonate pathway in cancer. Nat. Rev. Cancer 16, 718\u2013731 (2016).","journal-title":"Nat. Rev. Cancer"},{"key":"65888_CR42","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1038\/s41577-018-0094-3","volume":"19","author":"SP Parihar","year":"2019","unstructured":"Parihar, S. P., Guler, R. & Brombacher, F. Statins: a viable candidate for host-directed therapy against infectious diseases. Nat. Rev. Immunol. 19, 104\u2013117 (2019).","journal-title":"Nat. Rev. Immunol."},{"key":"65888_CR43","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1038\/s41582-023-00864-5","volume":"19","author":"M Valenza","year":"2023","unstructured":"Valenza, M., Birolini, G. & Cattaneo, E. The translational potential of cholesterol-based therapies for neurological disease. Nat. Rev. Neurol. 19, 583\u2013598 (2023).","journal-title":"Nat. Rev. Neurol."},{"key":"65888_CR44","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-21884-z","volume":"12","author":"AF Aissa","year":"2021","unstructured":"Aissa, A. F. et al. Single-cell transcriptional changes associated with drug tolerance and response to combination therapies in cancer. Nat. Commun. 12, 1628 (2021).","journal-title":"Nat. Commun."},{"key":"65888_CR45","doi-asserted-by":"publisher","DOI":"10.1016\/j.xpro.2024.102928","volume":"5","author":"M Clements","year":"2024","unstructured":"Clements, M., Simpson Ragdale, H., Garcia-Diaz, C. & Parrinello, S. Generation of immunocompetent somatic glioblastoma mouse models through in situ transformation of subventricular zone neural stem cells. STAR Protoc. 5, 102928 (2024).","journal-title":"STAR Protoc."},{"key":"65888_CR46","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2023.112472","volume":"42","author":"C Garcia-Diaz","year":"2023","unstructured":"Garcia-Diaz, C. et al. Glioblastoma cell fate is differentially regulated by the microenvironments of the tumor bulk and infiltrative margin. Cell Rep. 42, 112472 (2023).","journal-title":"Cell Rep."},{"key":"65888_CR47","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1016\/j.ccell.2016.09.008","volume":"30","author":"GR Villa","year":"2016","unstructured":"Villa, G. R. et al. An LXR-Cholesterol Axis Creates a Metabolic Co-Dependency for Brain Cancers. Cancer Cell 30, 683\u2013693 (2016).","journal-title":"Cancer Cell"},{"key":"65888_CR48","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1093\/neuonc\/noab162","volume":"24","author":"DM Burgenske","year":"2022","unstructured":"Burgenske, D. M. et al. Preclinical modeling in glioblastoma patient-derived xenograft (GBM PDX) xenografts to guide clinical development of lisavanbulin-a novel tumor checkpoint controller targeting microtubules. Neuro Oncol. 24, 384\u2013395 (2022).","journal-title":"Neuro Oncol."},{"key":"65888_CR49","doi-asserted-by":"publisher","first-page":"2264","DOI":"10.1158\/1078-0432.CCR-05-2510","volume":"12","author":"JN Sarkaria","year":"2006","unstructured":"Sarkaria, J. N. et al. Use of an orthotopic xenograft model for assessing the effect of epidermal growth factor receptor amplification on glioblastoma radiation response. Clin. Cancer Res 12, 2264\u20132271 (2006).","journal-title":"Clin. Cancer Res"},{"key":"65888_CR50","volume":"6","author":"B Dewdney","year":"2024","unstructured":"Dewdney, B. et al. Ion channel modulator DPI-201-106 significantly enhances antitumor activity of DNA damage response inhibitors in glioblastoma. Neurooncol Adv. 6, vdae187 (2024).","journal-title":"Neurooncol Adv."},{"key":"65888_CR51","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1016\/j.cell.2015.01.034","volume":"160","author":"CT Pineda","year":"2015","unstructured":"Pineda, C. T. et al. Degradation of AMPK by a cancer-specific ubiquitin ligase. Cell 160, 715\u2013728 (2015).","journal-title":"Cell"},{"key":"65888_CR52","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1038\/s41586-019-1472-0","volume":"572","author":"DN Debruyne","year":"2019","unstructured":"Debruyne, D. N. et al. BORIS promotes chromatin regulatory interactions in treatment-resistant cancer cells. Nature 572, 676\u2013680 (2019).","journal-title":"Nature"},{"key":"65888_CR53","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1016\/j.ccr.2013.05.003","volume":"23","author":"A Roesch","year":"2013","unstructured":"Roesch, A. et al. Overcoming Intrinsic Multidrug Resistance in Melanoma by Blocking the Mitochondrial Respiratory Chain of Slow-Cycling JARID1Bhigh Cells. Cancer Cell 23, 811\u2013825 (2013).","journal-title":"Cancer Cell"},{"key":"65888_CR54","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-30641-9","volume":"13","author":"H Chauvistr\u00e9","year":"2022","unstructured":"Chauvistr\u00e9, H. et al. Persister state-directed transitioning and vulnerability in melanoma. Nat. Commun. 13, 3055 (2022).","journal-title":"Nat. Commun."},{"key":"65888_CR55","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1038\/s41588-022-01047-6","volume":"54","author":"J Marsolier","year":"2022","unstructured":"Marsolier, J. et al. H3K27me3 conditions chemotolerance in triple-negative breast cancer. Nat. Genet. 54, 459\u2013468 (2022).","journal-title":"Nat. Genet."},{"key":"65888_CR56","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1038\/s41586-023-05780-8","volume":"615","author":"H Wang","year":"2023","unstructured":"Wang, H. et al. H3K4me3 regulates RNA polymerase II promoter-proximal pause-release. Nature 615, 339\u2013348 (2023).","journal-title":"Nature"},{"key":"65888_CR57","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1038\/s41591-019-0423-5","volume":"25","author":"Z Wang","year":"2019","unstructured":"Wang, Z. et al. Methionine is a metabolic dependency of tumor-initiating cells. Nat. Med. 25, 825\u2013837 (2019).","journal-title":"Nat. Med."},{"key":"65888_CR58","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1038\/nature21686","volume":"544","author":"S Han","year":"2017","unstructured":"Han, S. et al. Mono-unsaturated fatty acids link H3K4me3 modifiers to C. elegans lifespan. Nature 544, 185\u2013190 (2017).","journal-title":"Nature"},{"key":"65888_CR59","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-28469-4","volume":"13","author":"Q-L Wan","year":"2022","unstructured":"Wan, Q.-L. et al. Histone H3K4me3 modification is a transgenerational epigenetic signal for lipid metabolism in Caenorhabditis elegans. Nat. Commun. 13, 768 (2022).","journal-title":"Nat. Commun."},{"key":"65888_CR60","doi-asserted-by":"publisher","DOI":"10.1172\/JCI169993","volume":"133","author":"Z Zhao","year":"2023","unstructured":"Zhao, Z. et al. Therapeutic targeting of metabolic vulnerabilities in cancers with MLL3\/4-COMPASS epigenetic regulator mutations. J. Clin. Invest. 133, e169993 (2023).","journal-title":"J. Clin. Invest."},{"key":"65888_CR61","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.201910924","volume":"12","author":"M Han","year":"2020","unstructured":"Han, M. et al. Therapeutic implications of altered cholesterol homeostasis mediated by loss of CYP46A1 in human glioblastoma. EMBO Mol. Med. 12, e10924 (2020).","journal-title":"EMBO Mol. Med."},{"key":"65888_CR62","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1016\/j.tem.2013.12.007","volume":"25","author":"H Moon","year":"2014","unstructured":"Moon, H., Hill, M. M., Roberts, M. J., Gardiner, R. A. & Brown, A. J. Statins: protectors or pretenders in prostate cancer?. Trends Endocrinol. Metab. 25, 188\u2013196 (2014).","journal-title":"Trends Endocrinol. Metab."},{"key":"65888_CR63","doi-asserted-by":"publisher","unstructured":"Choudhury C. et al. Shared molecular regulation of quiescence in neural and glioma stem cells reveals therapeutic vulnerabilities. bioRxiv, 2025.2001.2022.634421 https:\/\/doi.org\/10.1101\/2025.01.22.634421 (2025).","DOI":"10.1101\/2025.01.22.634421"},{"key":"65888_CR64","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-32448-0","volume":"13","author":"F Antonica","year":"2022","unstructured":"Antonica, F. et al. A slow-cycling\/quiescent cells subpopulation is involved in glioma invasiveness. Nat. Commun. 13, 4767 (2022).","journal-title":"Nat. Commun."},{"key":"65888_CR65","doi-asserted-by":"publisher","DOI":"10.1093\/gigascience\/giz106","volume":"8","author":"Y Lin","year":"2019","unstructured":"Lin, Y. et al. Evaluating stably expressed genes in single cells. GigaScience 8, giz106 (2019).","journal-title":"GigaScience"},{"key":"65888_CR66","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1093\/bioinformatics\/btq054","volume":"26","author":"B MacLean","year":"2010","unstructured":"MacLean, B. et al. Skyline: an open source document editor for creating and analyzing targeted proteomics experiments. Bioinformatics 26, 966\u2013968 (2010).","journal-title":"Bioinformatics"},{"key":"65888_CR67","first-page":"13.17.11","volume":"13","author":"B Frewen","year":"2007","unstructured":"Frewen, B. & MacCoss, M. J. Using BiblioSpec for creating and searching tandem MS peptide libraries. Curr. Protoc. Bioinforma. Chapter 13, 13.17.11\u201313.17.12 (2007).","journal-title":"Curr. Protoc. Bioinforma. Chapter"},{"key":"65888_CR68","doi-asserted-by":"crossref","unstructured":"Lin S., Garcia B. A. Chapter One - Examining Histone Posttranslational Modification Patterns by High-Resolution Mass Spectrometry. In: Methods in Enzymology (eds Wu C., Allis C. D.). Academic Press (2012).","DOI":"10.1016\/B978-0-12-391940-3.00001-9"},{"key":"65888_CR69","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1093\/biostatistics\/kxj037","volume":"8","author":"WE Johnson","year":"2007","unstructured":"Johnson, W. E., Li, C. & Rabinovic, A. Adjusting batch effects in microarray expression data using empirical Bayes methods. Biostatistics 8, 118\u2013127 (2007).","journal-title":"Biostatistics"},{"key":"65888_CR70","doi-asserted-by":"publisher","first-page":"W202","DOI":"10.1093\/nar\/gkp335","volume":"37","author":"TL Bailey","year":"2009","unstructured":"Bailey, T. L. et al. MEME SUITE: tools for motif discovery and searching. Nucleic Acids Res 37, W202\u2013W208 (2009).","journal-title":"Nucleic Acids Res"},{"key":"65888_CR71","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1186\/s40478-023-01544-7","volume":"11","author":"OC Marian","year":"2023","unstructured":"Marian, O. C. et al. Disrupted myelin lipid metabolism differentiates frontotemporal dementia caused by GRN and C9orf72 gene mutations. Acta Neuropathol. Commun. 11, 52 (2023).","journal-title":"Acta Neuropathol. Commun."},{"key":"65888_CR72","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1186\/s13024-023-00650-3","volume":"18","author":"JY Lee","year":"2023","unstructured":"Lee, J. Y. et al. The major TMEM106B dementia risk allele affects TMEM106B protein levels, fibril formation, and myelin lipid homeostasis in the ageing human hippocampus. Mol. Neurodegener. 18, 63 (2023).","journal-title":"Mol. Neurodegener."},{"key":"65888_CR73","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1089\/crispr.2021.0113","volume":"5","author":"D Conant","year":"2022","unstructured":"Conant, D. et al. Inference of CRISPR Edits from Sanger Trace Data. Crispr j. 5, 123\u2013130 (2022).","journal-title":"Crispr j."},{"key":"65888_CR74","doi-asserted-by":"publisher","first-page":"D463","DOI":"10.1093\/nar\/gkv1042","volume":"44","author":"M Sud","year":"2016","unstructured":"Sud, M. et al. Metabolomics Workbench: An international repository for metabolomics data and metadata, metabolite standards, protocols, tutorials and training, and analysis tools. Nucleic Acids Res 44, D463\u2013D470 (2016).","journal-title":"Nucleic Acids Res"},{"key":"65888_CR75","doi-asserted-by":"publisher","unstructured":"Munoz L., Joun G. L. RStudio Coding for Data Visualisation in \u201cHistone methyltransferase PRDM9 promotes survival of drug-tolerant persister cells in glioblastoma\u201d. Zenodo https:\/\/doi.org\/10.5281\/zenodo.17248509 (2025).","DOI":"10.5281\/zenodo.17248509"},{"key":"65888_CR76","doi-asserted-by":"publisher","unstructured":"Munoz L., Joun G. L. Python Command Line Scripts for ChIP-seq data visualisation in \u201cHistone methyltransferase PRDM9 promotes survival of drug-tolerant persister cells in glioblastoma\u201d. Zenodo https:\/\/doi.org\/10.5281\/zenodo.17282725 (2025).","DOI":"10.5281\/zenodo.17282725"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-65888-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-65888-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-65888-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T10:02:20Z","timestamp":1765792940000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-65888-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,15]]},"references-count":76,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["65888"],"URL":"https:\/\/doi.org\/10.1038\/s41467-025-65888-5","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,15]]},"assertion":[{"value":"17 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"L.M., M.K. and W.T.J. are inventors on two patents related to the discovery and development of brain permeable microtubule-targeting agents, including CMPD1 and WJA88 used in this study (WO2016\/119017; WO2019\/148244). G.L.J., B.C., M.K. and L.M. are inventors on PCT\/AU2024\/050979 which covers the drug combinations described in this study for therapeutic use in cancer. E.G. received research funds from AZ and Prelude Therapeutics (for unrelated projects), EG is a cofounder and shareholder of Immunoa Pte.Ltd and cofounder shareholder, consultant, and advisory board member of Prometeo Therapeutics. Other authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"10905"}}